JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Thermo Fisher Scientific (NYSE:TMO) Stock

Thermo Fisher Scientific (NYSE:TMO) had its target price hoisted by analysts at JPMorgan Chase & Co. from $600.00 to $650.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 23.82% from the company’s current price.

Several other equities research analysts have also issued reports on the company. UBS Group upped their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research report on Wednesday. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Evercore ISI increased their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $593.43.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $524.95 on Thursday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market cap of $198.23 billion, a P/E ratio of 30.36, a P/E/G ratio of 2.90 and a beta of 0.77. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $610.97. The stock’s 50 day simple moving average is $488.68 and its 200 day simple moving average is $448.39.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Diversified Enterprises LLC boosted its stake in Thermo Fisher Scientific by 1.6% during the third quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company’s stock valued at $684,000 after buying an additional 22 shares in the last quarter. Lester Murray Antman dba SimplyRich purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at $232,000. Fluent Financial LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at $1,231,000. Sound Income Strategies LLC lifted its holdings in shares of Thermo Fisher Scientific by 120.3% during the third quarter. Sound Income Strategies LLC now owns 130 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 71 shares during the last quarter. Finally, Thomasville National Bank lifted its holdings in shares of Thermo Fisher Scientific by 4.6% during the third quarter. Thomasville National Bank now owns 36,121 shares of the medical research company’s stock valued at $17,519,000 after purchasing an additional 1,592 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.